文献速递心境障碍会诊联络精神医学

氯胺酮输注快速减轻抑郁发作自杀与抑郁症状:系统综述与荟萃分析

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该系统综述与荟萃分析纳入26项RCT共1166例抑郁发作患者,发现单次或重复静脉氯胺酮输注在急性期可显著降低自杀与抑郁症状,严重不良事件与干预无关,但长期结局尚不明确。

要点

  • 单次氯胺酮输注后24小时和1个月自杀症状显著低于对照。
  • 单次输注后4小时至1周抑郁症状显著改善,重复输注治疗结束时亦显著。
  • 报告严重不良事件与干预无关,其他不良事件短暂且试验期间缓解。

核心结论

  • 单次和重复静脉氯胺酮输注在急性期可有效减轻抑郁发作患者的自杀和抑郁症状。
  • 长期结局尚未充分确立。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、PsycInfo、Cochrane Library和Embase自建库至2025年11月7日,无语言限制。
  • 纳入26项随机临床试验,共1166例抑郁发作患者,其中氯胺酮组626例、对照组540例。
  • 采用Hedges g标准化均数差和随机效应模型分析,并进行了多项亚组分析。

主要发现

  • 单次氯胺酮输注对比对照,24小时自杀症状SMD为-0.69(95%CI,-0.98至-0.40),1个月为-0.70(95%CI,-1.17至-0.24)。
  • 重复氯胺酮输注治疗结束时自杀症状SMD为-0.72(95%CI,-1.00至-0.43)。
  • 单次输注后抑郁症状在4小时SMD为-1.74(95%CI,-2.43至-1.06)、24小时为-1.15(95%CI,-1.58至-0.72)、3天为-0.97(95%CI,-1.73至-0.20)、1周为-0.89(95%CI,-1.65至-0.13)。
  • 重复输注治疗结束时抑郁症状SMD为-0.81(95%CI,-1.16至-0.46)。
  • 报告的严重不良事件(如住院和死亡)与干预无关,其他不良事件(如头痛)短暂且在试验期间缓解。

临床怎么用

  • 对于抑郁发作急性期的自杀和抑郁症状,可考虑静脉氯胺酮输注作为快速减轻症状的辅助治疗选项。
  • 需注意氯胺酮在美国食品药品监督管理局(FDA)尚未批准,用于自杀和抑郁症状属超说明书使用。
  • 治疗期间应监测不良事件,严重不良事件虽与干预无关,但其他不良事件如头痛可能发生。

局限性

  • 长期结局尚未充分确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While intravenous ketamine is not approved by the US Food and Drug Administration, it is increasingly used with off-label indications as a novel treatment for suicidal and depressive symptoms. OBJECTIVE: To systematically review and metasynthesize the efficacy and safety data for intravenous ketamine in treating major depressive episodes (MDEs). DATA SOURCES: PubMed, PsycInfo, Cochrane Library, and Embase were systematically searched from database inception through November 7, 2025, with no language limits. STUDY SELECTION: Randomized clinical trials (RCTs) with (1) diagnosis of an MDE; (2) intervention and comparator groups consisting of intravenous ketamine and controls (eg, saline or midazolam); and (3) suicidal and depressive symptoms as efficacy outcomes were included. DATA EXTRACTION AND SYNTHESIS: Hedges g standardized mean differences (SMDs) were used to analyze improvement in suicidal and depressive symptoms using random-effects models. Multiple subgroup analyses were also conducted. MAIN OUTCOMES AND MEASURES: The main outcomes included the following: (1) changes in suicidal and depressive symptoms; (2) response and remission rates of depressive symptoms; and (3) safety measures (eg, adverse events and serious adverse events). RESULTS: A total of 26 RCTs comprising 1166 patients with an MDE (n = 626 receiving ketamine and n = 540 as control patients) were included. For suicidal symptoms, patients receiving a single ketamine infusion, compared with control patients, had significantly lower symptoms at 24 hours (SMD, -0.69 [95% CI, -0.98 to -0.40]) and at 1 month (SMD, -0.70 [95% CI, -1.17 to -0.24]). Those with repeated ketamine infusions showed a similar reduction of suicidal symptoms at the end of the treatment (SMD, -0.72 [95% CI, -1.00 to -0.43]). For depressive symptoms, significant reductions were shown at 4 hours (SMD, -1.74 [95% CI, -2.43 to -1.06]), 24 hours (SMD, -1.15 [95% CI, -1.58 to -0.72]), 3 days (SMD, -0.97 [95% CI, -1.73 to -0.20]), and 1 week (SMD, -0.89 [95% CI, -1.65 to -0.13]) after a single ketamine infusion and at the end of the treatment after repeated infusions (SMD, -0.81 [95% CI, -1.16 to -0.46]). Reported serious adverse events (eg, hospitalizations and deaths) were unrelated to the interventions, and other adverse events (eg, headache) were transient and resolved during the trials. CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that single and repeated intravenous ketamine infusions are efficacious in reducing suicidal and depressive symptoms in patients with an MDE in the acute phase, while longer-term outcomes are not well established.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2026. PMID: 42090166. doi:10.1001/jamapsychiatry.2026.0612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。